Dosing & Uses
Dosage Forms & Strengths
tablet
- 4mg
oral solution
- 4mg/5mL
oral suspension, extended-release (Karbinal ER)
- 4mg/5mL
Allergies
4-8 mg PO q6-8hr PO; not to exceed 24 mg/day
Karbinal ER: 6-16 mg (7.5-20 mL) PO q12hr
Other Indications & Uses
Seasonal & perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, urticaria & angioedema, dermatographism, anaphylactic reactions adjunctive to epinephrine, amelioration of the severity of allergic reactions to blood or plasma
Dosage Forms & Strengths
tablet
- 4mg
oral solution
- 4mg/5mL
oral suspension, extended-release (Karbinal ER)
- 4mg/5mL
Allergies
<2 years: Contraindicated
2-6 years: 0.2-0.4 mg/kg/day PO divided q6-8hr or 1-2 mg (2.5 mL) PO q6-8hr
>6 years: 2-4 mg (5-7.5 mL) PO q6-8hr
Karbinal ER
- <2 years: Contraindicated
- 2-3 years: 3-4 mg (3.75-5 mL) PO q12hr
- 4-5 years: 3-8 mg (3.75-10 mL) PO q12hr
- 6-11 years: 6-12 mg (7.5-15 mL) PO q12hr
- ≥12 years: 6-16 mg (7.5-20 mL) PO q12hr
Start at lower end of dosage range (4-8 mg PO q6-8hr) and decrease frequency if needed
Nonanticholinergic antihistamines should be considered first when treating allergic reactions (Beers Criteria)
Avoid use in elderly because of high incidence of anticholinergic effects
Clearance reduced with advanced age, greater risk of confusion, dry mouth, constipation, and other anticholinergic effects and toxicity
May exacerbate existing lower urinary conditions or benign prostatic hyperplasia
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (9)
- calcium/magnesium/potassium/sodium oxybates
carbinoxamine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- eluxadoline
carbinoxamine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.
- isocarboxazid
isocarboxazid increases effects of carbinoxamine by Other (see comment). Avoid or Use Alternate Drug. Comment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
- metoclopramide intranasal
carbinoxamine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
carbinoxamine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- pitolisant
carbinoxamine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.
- selinexor
selinexor, carbinoxamine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- sodium oxybate
carbinoxamine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- tranylcypromine
tranylcypromine increases effects of carbinoxamine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
Monitor Closely (210)
- acrivastine
acrivastine and carbinoxamine both increase sedation. Use Caution/Monitor.
- albuterol
carbinoxamine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
carbinoxamine and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
carbinoxamine and alprazolam both increase sedation. Use Caution/Monitor.
- amisulpride
amisulpride and carbinoxamine both increase sedation. Use Caution/Monitor.
- amitriptyline
carbinoxamine and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
carbinoxamine and amobarbital both increase sedation. Use Caution/Monitor.
- amoxapine
carbinoxamine and amoxapine both increase sedation. Use Caution/Monitor.
- apomorphine
carbinoxamine and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
carbinoxamine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
carbinoxamine and aripiprazole both increase sedation. Use Caution/Monitor.
- armodafinil
carbinoxamine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine and carbinoxamine both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and carbinoxamine both increase sedation. Use Caution/Monitor.
- avapritinib
avapritinib and carbinoxamine both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and carbinoxamine both increase sedation. Use Caution/Monitor.
- baclofen
carbinoxamine and baclofen both increase sedation. Use Caution/Monitor.
- belladonna and opium
carbinoxamine and belladonna and opium both increase sedation. Use Caution/Monitor.
- benperidol
carbinoxamine and benperidol both increase sedation. Use Caution/Monitor.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen and carbinoxamine both increase sedation. Use Caution/Monitor.
- benzphetamine
carbinoxamine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexanolone
brexanolone, carbinoxamine. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and carbinoxamine both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and carbinoxamine both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and carbinoxamine both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and carbinoxamine both increase sedation. Use Caution/Monitor.
- buprenorphine
carbinoxamine and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
carbinoxamine and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
buprenorphine subdermal implant and carbinoxamine both increase sedation. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and carbinoxamine both increase sedation. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and carbinoxamine both increase sedation. Use Caution/Monitor.
- butabarbital
carbinoxamine and butabarbital both increase sedation. Use Caution/Monitor.
- butalbital
carbinoxamine and butalbital both increase sedation. Use Caution/Monitor.
- butorphanol
carbinoxamine and butorphanol both increase sedation. Use Caution/Monitor.
- caffeine
carbinoxamine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carisoprodol
carbinoxamine and carisoprodol both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, carbinoxamine. Either increases effects of the other by sedation. Use Caution/Monitor.
- chloral hydrate
carbinoxamine and chloral hydrate both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
carbinoxamine and chlordiazepoxide both increase sedation. Use Caution/Monitor.
- chlorpheniramine
carbinoxamine and chlorpheniramine both increase sedation. Use Caution/Monitor.
- chlorpromazine
carbinoxamine and chlorpromazine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
carbinoxamine and chlorzoxazone both increase sedation. Use Caution/Monitor.
- cinnarizine
carbinoxamine and cinnarizine both increase sedation. Use Caution/Monitor.
- clemastine
carbinoxamine and clemastine both increase sedation. Use Caution/Monitor.
- clobazam
carbinoxamine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
carbinoxamine and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
carbinoxamine and clonazepam both increase sedation. Use Caution/Monitor.
- clorazepate
carbinoxamine and clorazepate both increase sedation. Use Caution/Monitor.
- clozapine
carbinoxamine and clozapine both increase sedation. Use Caution/Monitor.
- codeine
carbinoxamine and codeine both increase sedation. Use Caution/Monitor.
- cyclizine
carbinoxamine and cyclizine both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
carbinoxamine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
carbinoxamine and cyproheptadine both increase sedation. Use Caution/Monitor.
- dantrolene
carbinoxamine and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
carbinoxamine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- desflurane
desflurane and carbinoxamine both increase sedation. Use Caution/Monitor.
- desipramine
carbinoxamine and desipramine both increase sedation. Use Caution/Monitor.
- deutetrabenazine
carbinoxamine and deutetrabenazine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
carbinoxamine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
carbinoxamine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
carbinoxamine and dexmedetomidine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
carbinoxamine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
carbinoxamine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextromoramide
carbinoxamine and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
carbinoxamine and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
carbinoxamine and diazepam both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, carbinoxamine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- diethylpropion
carbinoxamine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and carbinoxamine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
carbinoxamine and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
carbinoxamine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- diphenhydramine
carbinoxamine and diphenhydramine both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
carbinoxamine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
carbinoxamine and dipipanone both increase sedation. Use Caution/Monitor.
- dobutamine
carbinoxamine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, carbinoxamine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dopamine
carbinoxamine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
carbinoxamine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
carbinoxamine and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
carbinoxamine and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
carbinoxamine and doxylamine both increase sedation. Use Caution/Monitor.
- droperidol
carbinoxamine and droperidol both increase sedation. Use Caution/Monitor.
- ephedrine
carbinoxamine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine
carbinoxamine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine racemic
carbinoxamine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, carbinoxamine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
carbinoxamine and estazolam both increase sedation. Use Caution/Monitor.
- ethanol
carbinoxamine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and carbinoxamine both increase sedation. Use Caution/Monitor.
- fenfluramine
carbinoxamine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fentanyl
fentanyl, carbinoxamine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
fentanyl and carbinoxamine both increase sedation. Use Caution/Monitor. - fentanyl intranasal
fentanyl intranasal, carbinoxamine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
fentanyl intranasal and carbinoxamine both increase sedation. Use Caution/Monitor. - fentanyl iontophoretic transdermal system
fentanyl iontophoretic transdermal system and carbinoxamine both increase sedation. Use Caution/Monitor.
- fentanyl transdermal
fentanyl transdermal, carbinoxamine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
fentanyl transdermal and carbinoxamine both increase sedation. Use Caution/Monitor. - fentanyl transmucosal
fentanyl transmucosal, carbinoxamine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- flibanserin
carbinoxamine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.
- fluphenazine
carbinoxamine and fluphenazine both increase sedation. Use Caution/Monitor.
- flurazepam
carbinoxamine and flurazepam both increase sedation. Use Caution/Monitor.
- formoterol
carbinoxamine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- gabapentin
gabapentin, carbinoxamine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, carbinoxamine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
carbinoxamine and ganaxolone both increase sedation. Use Caution/Monitor.
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, carbinoxamine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- gotu kola
gotu kola increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- haloperidol
carbinoxamine and haloperidol both increase sedation. Use Caution/Monitor.
- hawthorn
hawthorn increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hops
hops increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hyaluronidase
carbinoxamine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.
- hydromorphone
carbinoxamine and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
carbinoxamine and hydroxyzine both increase sedation. Use Caution/Monitor.
- iloperidone
carbinoxamine and iloperidone both increase sedation. Use Caution/Monitor.
- imipramine
carbinoxamine and imipramine both increase sedation. Use Caution/Monitor.
- isoproterenol
carbinoxamine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- kava
kava increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- ketamine
ketamine and carbinoxamine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
carbinoxamine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, carbinoxamine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, carbinoxamine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
carbinoxamine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levorphanol
carbinoxamine and levorphanol both increase sedation. Use Caution/Monitor.
- lisdexamfetamine
carbinoxamine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofepramine
carbinoxamine and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
carbinoxamine and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
carbinoxamine and loprazolam both increase sedation. Use Caution/Monitor.
- lorazepam
carbinoxamine and lorazepam both increase sedation. Use Caution/Monitor.
- lormetazepam
carbinoxamine and lormetazepam both increase sedation. Use Caution/Monitor.
- loxapine
carbinoxamine and loxapine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
carbinoxamine and loxapine inhaled both increase sedation. Use Caution/Monitor.
- lurasidone
lurasidone, carbinoxamine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
carbinoxamine and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
carbinoxamine and marijuana both increase sedation. Use Caution/Monitor.
- melatonin
carbinoxamine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
carbinoxamine and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
carbinoxamine and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
carbinoxamine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
carbinoxamine and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
carbinoxamine and methadone both increase sedation. Use Caution/Monitor.
- methamphetamine
carbinoxamine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
carbinoxamine and methocarbamol both increase sedation. Use Caution/Monitor.
- methylenedioxymethamphetamine
carbinoxamine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midazolam
carbinoxamine and midazolam both increase sedation. Use Caution/Monitor.
- midodrine
carbinoxamine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mirtazapine
carbinoxamine and mirtazapine both increase sedation. Use Caution/Monitor.
- modafinil
carbinoxamine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
carbinoxamine and morphine both increase sedation. Use Caution/Monitor.
- motherwort
carbinoxamine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
carbinoxamine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
carbinoxamine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
carbinoxamine and nalbuphine both increase sedation. Use Caution/Monitor.
- norepinephrine
carbinoxamine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
carbinoxamine and nortriptyline both increase sedation. Use Caution/Monitor.
- olanzapine
carbinoxamine and olanzapine both increase sedation. Use Caution/Monitor.
- opium tincture
carbinoxamine and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
carbinoxamine and orphenadrine both increase sedation. Use Caution/Monitor.
- oxazepam
carbinoxamine and oxazepam both increase sedation. Use Caution/Monitor.
- oxycodone
carbinoxamine and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
carbinoxamine and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
carbinoxamine and paliperidone both increase sedation. Use Caution/Monitor.
- papaveretum
carbinoxamine and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
carbinoxamine and papaverine both increase sedation. Use Caution/Monitor.
- passion flower
passion flower increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- pentazocine
carbinoxamine and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
carbinoxamine and pentobarbital both increase sedation. Use Caution/Monitor.
- perphenazine
carbinoxamine and perphenazine both increase sedation. Use Caution/Monitor.
- phendimetrazine
carbinoxamine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenelzine
phenelzine increases effects of carbinoxamine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .
- phenobarbital
carbinoxamine and phenobarbital both increase sedation. Use Caution/Monitor.
- phentermine
carbinoxamine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
carbinoxamine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine PO
carbinoxamine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
carbinoxamine and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
carbinoxamine and pimozide both increase sedation. Use Caution/Monitor.
- pirbuterol
carbinoxamine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pregabalin
pregabalin, carbinoxamine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
carbinoxamine and primidone both increase sedation. Use Caution/Monitor.
- prochlorperazine
carbinoxamine and prochlorperazine both increase sedation. Use Caution/Monitor.
- promethazine
carbinoxamine and promethazine both increase sedation. Use Caution/Monitor.
- propofol
propofol and carbinoxamine both increase sedation. Use Caution/Monitor.
- propylhexedrine
carbinoxamine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
carbinoxamine and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
carbinoxamine and quazepam both increase sedation. Use Caution/Monitor.
- quetiapine
carbinoxamine and quetiapine both increase sedation. Use Caution/Monitor.
- ramelteon
carbinoxamine and ramelteon both increase sedation. Use Caution/Monitor.
- risperidone
carbinoxamine and risperidone both increase sedation. Use Caution/Monitor.
- salmeterol
carbinoxamine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scullcap
carbinoxamine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
carbinoxamine and secobarbital both increase sedation. Use Caution/Monitor.
- sevoflurane
sevoflurane and carbinoxamine both increase sedation. Use Caution/Monitor.
- shepherd's purse
carbinoxamine and shepherd's purse both increase sedation. Use Caution/Monitor.
- stiripentol
stiripentol, carbinoxamine. Either increases effects of the other by sedation. Use Caution/Monitor. Concurrent use of medications with CNS depressant effects together with thalidomide should be avoided due to the risk for additive sedative effects.
- sufentanil
carbinoxamine and sufentanil both increase sedation. Use Caution/Monitor.
- tapentadol
carbinoxamine and tapentadol both increase sedation. Use Caution/Monitor.
- temazepam
carbinoxamine and temazepam both increase sedation. Use Caution/Monitor.
- terbutaline
carbinoxamine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
carbinoxamine and thioridazine both increase sedation. Use Caution/Monitor.
- thiothixene
carbinoxamine and thiothixene both increase sedation. Use Caution/Monitor.
- topiramate
carbinoxamine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
carbinoxamine and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
carbinoxamine and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
carbinoxamine and triazolam both increase sedation. Use Caution/Monitor.
- triclofos
carbinoxamine and triclofos both increase sedation. Use Caution/Monitor.
- trifluoperazine
carbinoxamine and trifluoperazine both increase sedation. Use Caution/Monitor.
- trimipramine
carbinoxamine and trimipramine both increase sedation. Use Caution/Monitor.
- triprolidine
carbinoxamine and triprolidine both increase sedation. Use Caution/Monitor.
- valerian
valerian increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- xylometazoline
carbinoxamine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
carbinoxamine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
carbinoxamine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
carbinoxamine and ziprasidone both increase sedation. Use Caution/Monitor.
- zotepine
carbinoxamine and zotepine both increase sedation. Use Caution/Monitor.
Minor (6)
- ashwagandha
ashwagandha increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
- brimonidine
brimonidine increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- eucalyptus
carbinoxamine and eucalyptus both increase sedation. Minor/Significance Unknown.
- nettle
nettle increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.
- sage
carbinoxamine and sage both increase sedation. Minor/Significance Unknown.
- Siberian ginseng
Siberian ginseng increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
Adverse Effects
Varies in incidence & severity with the individual drug; also individual patients vary in susceptibility
Frequency Not Defined
CNS depression
Drowsiness
Sedation ranging from mild drowsiness to deep sleep (most frequent)
Dizziness
Lassitude
Disturbed coordination
Muscular weakness
Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common
Epigastric distress
Anorexia
Nausea
Vomiting
Diarrhea
Constipation
Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare
Tachycardia, palpitation ECG changes (eg, widened QRS)
Arrhythmias (eg, extrasystole, heart block)
Hypotension
Hypertension
Dizziness, sedation, and hypotension may occur in geriatric patients
Dryness of mouth, nose, and throat
Dysuria
Urinary retention
Impotence
Vertigo
Visual disturbances
Blurred vision
Diplopia; tinnitus
Acute labyrinthitis
Insomnia
Tremors
Nervousness
Irritability
Facial dyskinesia
Tightness of the chest
Thickening of bronchial secretions
Wheezing
Nasal stuffiness
Sweating
Chills
Early menses
Toxic psychosis
Headache
Faintness
Paresthesia
Agranulocytosis
Hemolytic anemia
Leukopenia
Thrombocytopenia
Pancytopenia
Warnings
Contraindications
Hypersensitivity
Concurrent therapy with MAO inhibitors
Children ≤2 years
Cautions
Deaths reported in children 2 years of age and younger treated with carbinoxamine-containing medications; therefore, contraindicated in children aged ≤2 years
May produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery;
Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of drug; avoid concurrent use of drug with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur
Drug has anticholinergic (atropine-like) properties and, therefore, should be used with caution in patients with increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction
Drug contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in susceptible individuals; the overall prevalence of sulfite sensitivity in the general population is unknown and probably low; sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic individuals
Drug interactions overview
-
CNS depressants
- Avoid coadministration
- Alcohol or other CNS depressants may potentiate the impairment of CNS performance
-
Monoamine oxidase inhibitors
- Avoid coadministration
- Monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines
Pregnancy & Lactation
Pregnancy
Published data over decades of use of antihistamines, including carbinoxamine, have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; however, published data specifically evaluating risk of carbinoxamine were not found
No animal reproductive studies have been conducted
Lactation
Based on physical properties of carbinoxamine, it is likely is present in breast milk
Drowsiness and irritability in infants exposed antihistamines via breast milk have been reported
Postmarketing reports of death in children <2 years exposed to oral carbinoxamine
No data are available on effects on milk production
Not recommended to breastfeed during treatment
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Histamine H1-receptor antagonist in blood vessels, respiratory tract, and gastrointestinal tract
Pharmacokinetics
Half-Life: 10-20 hr
Metabolism: Hepatic
Excretion: Urine
Administration
Oral Administration
Oral route only
Take on an empty stomach with water
Oral solution
- Measure with an accurate milliliter measuring device
- A household teaspoon is not an accurate measuring device and could lead to overdosage
- A pharmacist can provide an appropriate measuring device and can provide instructions for measuring correct dose
Storage
- Store at 20-25ºC (68-77ºF)
- Dispense in a tight, light-resistant container with a child-resistant closure
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
